Genentech at buy by Jefferies

Jefferies & Co., Inc. analyst Adam Walsh reiterated Genentech, Inc. at a buy on expectations of Avastin approval in lung and Herceptin approval in early breast cancer driving near-term out-performance. Also, the analyst says Avastin approval in breast cancer will provide multi-year, sustainable upside. The company will announce its third-quarter results on Tuesday. Shares of the South San Francisco, Calif.-based biotherapeutic company were up $3.08, or 3.70%, at $86.28. (NYSE: DNA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.